Category: 98416-72-9

Application In Synthesis of 6-Bromo-2-chloro-3-methylquinoxaline, New research progress on 98416-72-9 in 2021. As an important bridge between the micro and macro material world, chemistry is one of the main methods and means for humans to understand and transform the material world.98416-72-9, Name is 6-Bromo-2-chloro-3-methylquinoxaline, molecular formula is C9H6BrClN2. In a article，once mentioned of 98416-72-9

In an effort to develop potent anti-cancer agents, we have synthesized some substituted quinoxaline derivatives. Reaction of 6-bromo-3-methylquinoxalin-2(1H)-one 1 with aromatic aldehydes furnished the styryl derivatives 2a-e. Alkylation of 1 with ethyl chloroacetate produced the N-alkyl derivatives 3. Hydrazinolysis of the ester derivative 3 with hydrazine hydrate afforded the hydrazide derivative 4. In addition, chlorination of 1 with phosphorus oxychloride afforded the 2-chloro derivative 5 which was used as a key intermediate for the synthesis of substituted quinoxaline derivatives 6-8, N-pyrazole derivative 9, tetrazolo[1,5-a]quinoxaline derivative 10 and Schiff base derivatives 13, 15 via reaction with several nucleophiles reagents. Docking methodologies were used to predict their binding conformation to explain the differences of their tested biological activities. All the tested compounds were screened in vitro for their cytotoxic effect on three tumor cell lines. Some new quinoxaline derivatives were studied as inhibitors of c-Met kinase, a receptor associated with high tumor grade and poor prognosis in a number of human cancers. Compounds 2e, 4, 7a, 12a, 12b and 13 showed the highest binding affinity with CDOCKER energy score, while showed the lowest IC50 values against three types of cancer cell lines. It is worth to mention that, compounds 2e, 7a, 12b and 13 showed comparable inhibition activity to the reference drug, while compounds 4 and 12a showed a more potent inhibition activity than Doxorubicin.

We’ll also look at important developments in the pharmaceutical industry because understanding organic chemistry is important in understanding health, medicine, the role of 98416-72-9, and how the biochemistry of the body works.Application In Synthesis of 6-Bromo-2-chloro-3-methylquinoxaline

Reference：
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N1991 | ChemSpider

New Advances in Chemical Research, May 2021. Catalysts allow a reaction to proceed via a pathway that has a lower activation energy than the uncatalyzed reaction.Quality Control of 6-Bromo-2-chloro-3-methylquinoxaline, In a article, mentioned the application of 98416-72-9, Name is 6-Bromo-2-chloro-3-methylquinoxaline, molecular formula is C9H6BrClN2

The present invention is directed to triazolopyrazine compounds of Formula (I). Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds as therapeutic agents treating neurological and psychiatric disorders

Do you like my blog? If you like, you can also browse other articles about this kind. Thanks for taking the time to read the blog about 98416-72-9

Reference：
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N1989 | ChemSpider

New Advances in Chemical Research, May 2021. Catalysts allow a reaction to proceed via a pathway that has a lower activation energy than the uncatalyzed reaction.Related Products of 98416-72-9, In a article, mentioned the application of 98416-72-9, Name is 6-Bromo-2-chloro-3-methylquinoxaline, molecular formula is C9H6BrClN2

Novel 5-methyltetrazolo<1,5-a>quinoxalin-4-ones (5) and 5-methyl-1,2,4-triazolo<4,3-a>quinoxalin-4-ones (7) could be synthesized from 1-methyl-3-chloroquinoxalin-2-ones (3) and 1-methyl-3-hydrazinoquinoxalin-2-ones (6), respectively.Further extensive study was carried out to synthesize 4- or 7- substituted and 4,7-disubstituted tetrazolo<1,5-a>quinoxalines (10) and 1,2,4-triazolo<4,3-a>quinoxalines (12).

Balanced chemical reaction does not necessarily reveal either the individual elementary reactions by which a reaction occurs or its rate law.Related Products of 98416-72-9. In my other articles, you can also check out more blogs about 98416-72-9

Reference：
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N1993 | ChemSpider

Related Products of 98416-72-9, New research progress on 98416-72-9 in 2021. As an important bridge between the micro and macro material world, chemistry is one of the main methods and means for humans to understand and transform the material world.98416-72-9, Name is 6-Bromo-2-chloro-3-methylquinoxaline, molecular formula is C9H6BrClN2. In a article，once mentioned of 98416-72-9

Facile synthesis of novel 6-substituted 2-chloro-3-methylquinoxalines (4a-d) is described.Intramolecular cyclization reaction of 4-substituted 2-nitroacetoacetanilides (1a-d) in basic conditions afforded 6-substituted 2(1H)-quinoxalinone-4-oxides (2a-d) and in situ, which could be converted into novel 6-substituted 3-methyl-2(1H)-quinoxalinones (3a-d) using ethyl acetoacetate. 3a-d were chlorinated with phosphoryl chloride to afford 4a-d.

A reaction mechanism is the microscopic path by which reactants are transformed into products. Each step is an elementary reaction. In my other articles, you can also check out more blogs about 98416-72-9

Reference：
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N1992 | ChemSpider

Electric Literature of 98416-72-9, New research progress on 98416-72-9 in 2021. As an important bridge between the micro and macro material world, chemistry is one of the main methods and means for humans to understand and transform the material world.98416-72-9, Name is 6-Bromo-2-chloro-3-methylquinoxaline, molecular formula is C9H6BrClN2. In a article，once mentioned of 98416-72-9

The present invention relates to novel 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]-quinoxaline derivatives as inhibitors of phosphodiesterase 2 (PDE2) and to a lesser extent of phosphodiesterase 10 (PDE10) or as inhibitors of both, phosphodiesterases 2 and 10. The invention is also directed to harmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which PDE2 is involved, or disorders in which both PDE2 and PDE10 are involved, such as neurological and psychiatric disorders, and endocrinological or metabolic diseases. The present invention also relates to radiolabeled compounds which may be useful for imaging and quantifying the PDE2 enzyme in tissues, using positron- emission tomography (PET). The invention is also directed to compositions comprising such compounds, to processes for preparing such compounds and compositions, to the use of such com-pounds and compositions for imaging a tissue, cells or a host, in vitro or in vivo and to precursors of said compounds.

A reaction mechanism is the microscopic path by which reactants are transformed into products. Each step is an elementary reaction. In my other articles, you can also check out more blogs about 98416-72-9

Reference：
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N1990 | ChemSpider

In homogeneous catalysis, the catalyst is in the same phase as the reactant. The number of collisions between reactants and catalyst is at a maximum.In a patent, 98416-72-9, name is 6-Bromo-2-chloro-3-methylquinoxaline, introducing its new discovery. Quality Control of 6-Bromo-2-chloro-3-methylquinoxaline

Molecular modeling studies and synthesis of novel quinoxaline derivatives with potential anticancer activity as inhibitors of c-Met kinase

In an effort to develop potent anti-cancer agents, we have synthesized some substituted quinoxaline derivatives. Reaction of 6-bromo-3-methylquinoxalin-2(1H)-one 1 with aromatic aldehydes furnished the styryl derivatives 2a-e. Alkylation of 1 with ethyl chloroacetate produced the N-alkyl derivatives 3. Hydrazinolysis of the ester derivative 3 with hydrazine hydrate afforded the hydrazide derivative 4. In addition, chlorination of 1 with phosphorus oxychloride afforded the 2-chloro derivative 5 which was used as a key intermediate for the synthesis of substituted quinoxaline derivatives 6-8, N-pyrazole derivative 9, tetrazolo[1,5-a]quinoxaline derivative 10 and Schiff base derivatives 13, 15 via reaction with several nucleophiles reagents. Docking methodologies were used to predict their binding conformation to explain the differences of their tested biological activities. All the tested compounds were screened in vitro for their cytotoxic effect on three tumor cell lines. Some new quinoxaline derivatives were studied as inhibitors of c-Met kinase, a receptor associated with high tumor grade and poor prognosis in a number of human cancers. Compounds 2e, 4, 7a, 12a, 12b and 13 showed the highest binding affinity with CDOCKER energy score, while showed the lowest IC50 values against three types of cancer cell lines. It is worth to mention that, compounds 2e, 7a, 12b and 13 showed comparable inhibition activity to the reference drug, while compounds 4 and 12a showed a more potent inhibition activity than Doxorubicin.

We’ll also look at important developments in the pharmaceutical industry because understanding organic chemistry is important in understanding health, medicine, the role of 98416-72-9, and how the biochemistry of the body works.Quality Control of 6-Bromo-2-chloro-3-methylquinoxaline

Reference：
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N1991 | ChemSpider

Synthetic Route of 98416-72-9, The reaction rate of a catalyzed reaction is faster than the reaction rate of the uncatalyzed reaction at the same temperature.98416-72-9, Name is 6-Bromo-2-chloro-3-methylquinoxaline, molecular formula is C9H6BrClN2. In a Patent，once mentioned of 98416-72-9

1-ARYL-4-METHYL-[ 1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES

The present invention relates to novel 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]-quinoxaline derivatives as inhibitors of phosphodiesterase 2 (PDE2) and to a lesser extent of phosphodiesterase 10 (PDE10) or as inhibitors of both, phosphodiesterases 2 and 10. The invention is also directed to harmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which PDE2 is involved, or disorders in which both PDE2 and PDE10 are involved, such as neurological and psychiatric disorders, and endocrinological or metabolic diseases. The present invention also relates to radiolabeled compounds which may be useful for imaging and quantifying the PDE2 enzyme in tissues, using positron- emission tomography (PET). The invention is also directed to compositions comprising such compounds, to processes for preparing such compounds and compositions, to the use of such com-pounds and compositions for imaging a tissue, cells or a host, in vitro or in vivo and to precursors of said compounds.

A reaction mechanism is the microscopic path by which reactants are transformed into products. Each step is an elementary reaction. In my other articles, you can also check out more blogs about 98416-72-9

Reference：
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N1990 | ChemSpider

98416-72-9, Name is 6-Bromo-2-chloro-3-methylquinoxaline, belongs to quinoxaline compound, is a common compound. Product Details of 98416-72-9In an article, once mentioned the new application about 98416-72-9.

TRIAZOLOPYRAZINE DERIVATIVES AND THEIR USE FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS

The present invention is directed to triazolopyrazine compounds of Formula (I). Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds as therapeutic agents treating neurological and psychiatric disorders

Do you like my blog? If you like, you can also browse other articles about this kind. Thanks for taking the time to read the blog about 98416-72-9

Reference£º
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N1989 | ChemSpider

Electric Literature of 98416-72-9, A catalyst don’t appear in the overall stoichiometry of the reaction it catalyzes, but it must appear in at least one of the elementary reactions in the mechanism for the catalyzed reaction. 98416-72-9, Name is 6-Bromo-2-chloro-3-methylquinoxaline, molecular formula is C9H6BrClN2. In a Article£¬once mentioned of 98416-72-9

A FACILE SYNTHESIS OF NOVEL TRICYCLIC COMPOUNDS, TETRAZOLOQUINOXALINES AND 1,2,4-TRIAZOLOQUINOXALINES

Novel 5-methyltetrazolo<1,5-a>quinoxalin-4-ones (5) and 5-methyl-1,2,4-triazolo<4,3-a>quinoxalin-4-ones (7) could be synthesized from 1-methyl-3-chloroquinoxalin-2-ones (3) and 1-methyl-3-hydrazinoquinoxalin-2-ones (6), respectively.Further extensive study was carried out to synthesize 4- or 7- substituted and 4,7-disubstituted tetrazolo<1,5-a>quinoxalines (10) and 1,2,4-triazolo<4,3-a>quinoxalines (12).

Balanced chemical reaction does not necessarily reveal either the individual elementary reactions by which a reaction occurs or its rate law.Electric Literature of 98416-72-9. In my other articles, you can also check out more blogs about 98416-72-9

Reference£º
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N1993 | ChemSpider

98416-72-9, 6-Bromo-2-chloro-3-methylquinoxaline is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: To a solution of amino compound and K2CO3 (2.0 g) in acetonitrile(50 mL), compound 5 (0.01 mol) was added and the mixturewas refluxed for an appropriate time (16-20 h) (monitored byTLC). After completion of the reaction, the mixture was filteredand the excess of acetonitrile was evaporated under reduced pressureto get the product. The product was crystallized from benzeneto afford the corresponding compounds, 98416-72-9

98416-72-9 6-Bromo-2-chloro-3-methylquinoxaline 13487186, aquinoxaline compound, is more and more widely used in various fields.

Reference£º
Article; Abbas, Hebat-Allah S.; Al-Marhabi, Aisha R.; Eissa, Sally I.; Ammar, Yousry A.; Bioorganic and Medicinal Chemistry; vol. 23; 20; (2015); p. 6560 – 6572;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider